The in vitro experimental outcomes aligned with the predictions derived from NP, suggesting that gomisin B might be the primary active compound in Aidi injection for NB treatment, especially for patients with MYCN-amplified NB. The gene discussed is MYCN; the disease is neuroblastoma.